PCSK9 variants, LDL-cholesterol, and neurocognitive impairment: The REasons for Geographic And Racial Differences in Stroke (REGARDS) study

BACKGROUND: Despite concerns about adverse neurocognitive events raised by prior trials, pharmacologic PCSK9 inhibition was not associated with neurocognitive effects in a recent phase 3 randomized trial. PCSK9 loss-of-function (LOF) variants that result in life-long exposure to low LDL-C can provid...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Circulation
Main Authors: Mefford, Matthew T., Rosenson, Robert S., Cushman, Mary, Farkouh, Michael E., McClure, Leslie A., Wadley, Virginia G., Irvin, Marguerite R., Bittner, Vera, Safford, Monika M., Somaratne, Ransi, Monda, Keri L., Muntner, Paul, Levitan, Emily B.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5860959/
https://ncbi.nlm.nih.gov/pubmed/29146683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.117.029785
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares